Core Viewpoint - The Shanghai Consumer Protection Committee has exposed the "Tongrentang Antarctic Krill Oil" product for having a phospholipid content of 0, raising questions about the integrity of the brand and the supply chain involved in this alleged counterfeit case [1][3]. Group 1: Company Accountability - Beijing Tongrentang (Sichuan) Health Industry Co., Ltd. is questioned for purchasing the product at a price significantly lower than the normal cost of Antarctic krill oil, raising concerns about their quality control measures during product acceptance [3][4]. - The company has been criticized for not conducting thorough checks on the phospholipid content during the procurement process, which is essential for ensuring product quality [3]. - The company claims to be responsible for the products sold, stating that they are currently awaiting responses from relevant authorities regarding the testing of the product [4]. Group 2: Consumer Impact - Consumers are purchasing the product at a retail price of 50-60 yuan per bottle, while the procurement cost is only 3-4 yuan, highlighting a significant markup and questioning the ethical practices of the involved parties [3]. - The presence of such problematic products in the health functional food market not only harms consumer rights but also negatively impacts consumer confidence [3]. Group 3: Legal Actions - The controlling shareholder of Beijing Tongrentang Health Industry Co., Ltd. has announced that the involved product was used without authorization of the "Beijing Tongrentang" name, indicating potential legal violations, and has initiated legal proceedings against the involved companies [5].

Core Viewpoint - A product claiming to be "99% pure Antarctic krill oil" from "Beijing Tongrentang" was found to contain "0" krill oil, raising concerns about misleading marketing practices and consumer protection [1][3][12]. Group 1: Product Misrepresentation - The Shanghai Consumer Protection Commission tested 15 popular Antarctic krill oil products and discovered that the product in question had no actual krill oil content, despite claims of 43% phospholipid content [1][3]. - The manufacturer, Anhui Habao Pharmaceutical Co., admitted that the product was customized by the distributor, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., and did not contain the claimed krill oil [4][8]. - The product was sold at a price of 60 yuan per bottle, while the manufacturer's cost was only 3 to 3.7 yuan, raising questions about the legitimacy of the pricing and the quality of the ingredients [4][11]. Group 2: Misleading Branding - The packaging prominently featured "Beijing Tongrentang," which misled consumers into believing it was a product directly from the well-known brand, while it was actually from a different company [4][7]. - The product's branding utilized a design that closely resembled the core trademark of Beijing Tongrentang, creating a deceptive impression of authenticity [7][19]. - The distributor claimed that misleading packaging decisions were made by the manufacturer, while the manufacturer stated that the packaging was designed according to the distributor's specifications, indicating a shared responsibility for the misleading marketing [8][11]. Group 3: Broader Industry Implications - The incident is not isolated; there is a larger trend of "borderline" products using the Tongrentang name to mislead consumers, with similar products also found on e-commerce platforms [12][18]. - The Shanghai Consumer Protection Commission urged the distributor to conduct a self-examination, apologize to consumers, and recall the problematic products [19][20]. - Beijing Tongrentang Health Pharmaceutical Co. announced that it would stop the distribution of the implicated product and initiate legal action against the responsible parties for unauthorized use of its name [19][20].

Core Viewpoint - The article discusses the controversy surrounding the Beijing Tongrentang brand, particularly regarding the quality of its products and the implications of its private label business model, which allows for low-cost, flexible branding of health products [2][4][12]. Group 1: Brand and Product Quality Issues - A product labeled as "Beijing Tongrentang High Purity Antarctic Krill Oil" was found to contain zero phospholipid content, raising public concerns about the quality of Tongrentang products [5][12]. - The Shanghai Consumer Protection Committee is investigating the production company, Anhui Habao Pharmaceutical Co., and the distributor, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., for misleading claims [5][6]. - The packaging of the krill oil product prominently features the "Beijing Tongrentang" name, but it actually uses a different trademark owned by the distributor, which could mislead consumers [11][20]. Group 2: Business Model and Market Practices - The private label business model allows for low minimum order quantities, with initial orders starting at 10,000 boxes, enabling various products to be marketed under the Tongrentang brand [2][15]. - The article highlights that the core operation of the private label business involves brand authorization and contract manufacturing, with actual production outsourced to companies like Habao Pharmaceutical [13][28]. - The pricing strategy for these products can lead to significant markups on e-commerce platforms, with retail prices reaching 60 to over 90 yuan for products that cost much less to produce [17]. Group 3: Legal and Regulatory Responses - In response to the controversy, Tongrentang announced plans to sue the distributor for unauthorized use of its brand name, aiming to protect consumer rights and the company's reputation [4][12]. - The article notes a history of quality issues and regulatory penalties faced by Tongrentang and its subsidiaries, indicating a pattern of quality control failures [29][31]. - Legal experts suggest that Tongrentang has the right to take action against unauthorized use of its trademarks, emphasizing the importance of maintaining brand integrity and consumer trust [32].

Core Viewpoint - The recent controversy surrounding Tong Ren Tang's Antarctic krill oil product involves allegations of ingredient falsification, leading to significant scrutiny from consumer protection authorities and potential legal actions against the involved parties [1][2]. Group 1: Product Allegations - The product labeled as "Beijing Tong Ren Tang 99% High Purity Antarctic Krill Oil" was found to have a phospholipid content of 0, contradicting its claims [1]. - Anhui Habao Pharmaceutical Co., Ltd. admitted that it did not add the claimed "Antarctic krill oil" during production, raising concerns about intentional deception [2]. Group 2: Company Responses - Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical Co., Ltd. stated that they are conducting product testing and will take responsibility for consumer purchases [1]. - The Shanghai Consumer Protection Committee has urged Beijing Tong Ren Tang (Sichuan) to conduct a self-examination, inform consumers accurately, and issue an apology [2]. Group 3: Legal and Regulatory Actions - The parent company, Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd., has ordered the cessation of sales of the implicated product and initiated a full investigation [2]. - Legal proceedings have been initiated against the involved companies for unauthorized use of the "Beijing Tong Ren Tang" branding, which is considered illegal [2].

Core Viewpoint - The Shanghai Consumer Rights Protection Committee has accused Anhui Habio Pharmaceutical Co., Ltd. and Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. of potential fraud regarding the "99% High Purity Antarctic Krill Oil" product, highlighting serious discrepancies between product claims and actual content [1] Group 1: Company Actions - Anhui Habio Pharmaceutical admitted that the product did not contain the claimed "Antarctic krill oil" during production [1] - Beijing Tongrentang (Sichuan) Health claimed ignorance of the alleged fraudulent behavior and distanced itself from responsibility during the inquiry [1] Group 2: Investigation Findings - The Shanghai Consumer Rights Protection Committee found evidence of intentional fraud, noting that the product falsely claimed a phospholipid content of 43% while lacking the advertised ingredient [1] - The investigation revealed deliberate misleading practices in product packaging and marketing [1] Group 3: Recommendations - The Shanghai Consumer Rights Protection Committee has recommended that Beijing Tongrentang (Sichuan) Health conduct a self-examination, issue an apology for the infringement, recall the problematic products, and provide legal compensation [1]

Core Viewpoint - The incident involving a counterfeit Antarctic krill oil product has highlighted the branding issues and trust crisis faced by Tong Ren Tang, a well-known traditional Chinese medicine brand [1][3][4]. Group 1: Incident Overview - The Shanghai Consumer Protection Commission conducted tests on 15 popular Antarctic krill oil products, revealing that a product labeled as "Beijing Tong Ren Tang 99% high-purity Antarctic krill oil" had a phospholipid content of 0, indicating potential fraud [1][4]. - The product in question was not directly produced by Beijing Tong Ren Tang but was distributed by its subsidiary, Sichuan Health Pharmaceutical Co., Ltd., with manufacturing outsourced to Anhui Habio Pharmaceutical Co., Ltd., exemplifying a typical private label model [3][4]. - Following the investigation, Habio Pharmaceutical admitted to not adding the claimed "Antarctic krill oil" during production, and Sichuan Health Pharmaceutical was urged to conduct a self-examination and issue an apology to consumers [5][9]. Group 2: Brand Trust Crisis - Beijing Tong Ren Tang, with a history dating back to 1669, has faced multiple trust crises due to private label issues, leading to concerns about its brand management and quality control [3][4][7]. - The company has issued statements emphasizing that the problematic product was unauthorized and that it has initiated legal proceedings against the involved parties, attempting to distance itself from the issue [5][6]. - Experts suggest that the brand's response may not fully alleviate public concerns, as consumers may still associate the subsidiary's products with the Tong Ren Tang brand [6][7]. Group 3: Quality Control and Regulatory Issues - The incident has raised questions about the quality control measures in place for private label products, with calls for stricter oversight and a clearer delineation of brand responsibilities [8][9]. - Habio Pharmaceutical has been involved in multiple legal disputes and administrative penalties over the past three years, indicating ongoing compliance issues [9][10]. - Experts recommend that Habio Pharmaceutical establish a comprehensive compliance system and improve its production processes to prevent future incidents [10].

Core Viewpoint - The scandal surrounding Antarctic krill oil has highlighted the branding issues and quality control failures associated with Tongrentang, a well-known traditional Chinese medicine brand [2][4][11]. Group 1: Incident Overview - The Shanghai Consumer Protection Commission conducted tests on 15 popular Antarctic krill oil products, revealing that a product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" contained 0% phospholipid, indicating potential fraud [2][5]. - The implicated product was not directly produced by Beijing Tongrentang but was distributed by its subsidiary, Sichuan Health Pharmaceutical Co., Ltd., with manufacturing outsourced to Anhui Habio Pharmaceutical Co., Ltd., exemplifying a typical private label model [2][4]. - Following the investigation, both the distributor and manufacturer were summoned by the Shanghai Consumer Protection Commission, with Habio admitting to not including the claimed Antarctic krill oil in the production process [6][8]. Group 2: Brand Trust Crisis - Beijing Tongrentang, established in 1669, has faced multiple trust crises due to private label issues, leading to concerns about its brand management and quality control [4][11]. - The Antarctic krill oil market has seen a surge in popularity, but the wide price range and varying quality have made it difficult for consumers to discern reliable products [5][11]. - Experts suggest that the brand's response, which includes legal action against the involved companies and a reminder for consumers to verify the authenticity of the "Double Dragon" trademark, may not fully alleviate public skepticism [9][11]. Group 3: Regulatory and Compliance Issues - The Shanghai Consumer Protection Commission has urged Sichuan Health Pharmaceutical to conduct a self-examination, apologize to consumers, and recall the problematic products [8][12]. - The incident has raised questions about the accountability of Beijing Tongrentang regarding its subsidiaries and the need for clearer brand management and authorization boundaries [11][12]. - Experts recommend that Beijing Tongrentang establish a comprehensive quality control and traceability system to prevent future issues, including stricter oversight of its subsidiaries and private label products [13][15]. Group 4: Manufacturer's Legal Troubles - Anhui Habio Pharmaceutical, the manufacturer of the disputed krill oil, has been involved in multiple legal disputes, including trademark infringement cases, indicating a pattern of compliance issues [14][15]. - The company has faced administrative penalties for various violations, highlighting the need for a robust compliance framework to ensure product quality and legal adherence [15].

记者丨闫硕 编辑丨季媛媛 视频丨柳润瑛 见习记者陈泽锴 一款南极磷虾油引发的造假风波，再次将同仁堂贴牌乱象推向台前。 近日，上海市消保委对市面上热销的15款国内外南极磷虾油产品开展了检测和调查，其中一款标称"北京同仁堂99%高纯南极磷虾油"的产品，磷 脂含量为0，涉嫌造假。 这款涉事产品并非北京同仁堂直接生产，而是由其孙公司北京同仁堂（四川）健康药业有限公司（简称"四川健康药业"）负责经销，实际生产 代工方为安徽哈博药业有限公司（简称"哈博药业"），属于典型的贴牌模式。 12月15日下午，上海市消保委正式约谈了该产品的经销商与生产商，哈博药业承认在生产过程中未添加其对外宣称的"南极磷虾油"；产品包装 按照四川健康药业要求制作。 与此同时，同仁堂健康会员微信公众号发布声明：这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法程序，对涉 事企业进行起诉。目前，四川健康药业已停止经销该产品。 北京同仁堂是"同仁堂"商标唯一合法持有人，其起源可追溯至1669年，凭借数百年的品牌积淀成为中药行业老字号标杆。但近年来，北京同仁 堂多次因贴牌乱象陷入信任危机。有业内观点认为，其在品牌授权管理、子公司管控 ...

Core Viewpoint - The article discusses the controversy surrounding the Beijing Tongrentang brand, particularly regarding the quality of its health products, specifically a product labeled as "Beijing Tongrentang High Purity Antarctic Krill Oil," which was found to contain zero phospholipids, raising public concerns about product quality and brand integrity [2][5][10]. Group 1: Brand and Product Issues - The low entry barrier for private label products associated with the Beijing Tongrentang brand has led to a proliferation of various products on e-commerce platforms, with minimum order quantities as low as 10,000 boxes [2][10]. - A recent investigation revealed that a product claiming to contain high levels of phospholipids actually had none, indicating potential fraud and leading to scrutiny of the brand's quality control [5][10]. - The company has initiated legal action against its subsidiary, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., in response to the controversy, aiming to protect its brand image [4][10]. Group 2: Manufacturer and Regulatory Concerns - The manufacturer of the disputed krill oil product, Anhui Habao Pharmaceutical Co., has a history of administrative penalties and food safety issues, including multiple instances of non-compliance with food safety standards [7][9]. - The Shanghai Consumer Protection Committee has demanded explanations from both the manufacturer and the distributor regarding the product's actual content and quality [5][10]. - The article highlights the ongoing cycle of quality issues, penalties, and public relations efforts that have plagued the brand, questioning the effectiveness of legal actions in restoring consumer trust [26][28]. Group 3: Brand Authorization and Market Practices - The private label business model employed by subsidiaries of Beijing Tongrentang involves brand authorization and contract manufacturing, allowing for a wide range of products to be marketed under the brand name [10][12]. - The article notes that while the brand name is prominently displayed, the actual trademark used is different from the well-known Tongrentang logo, which may confuse consumers [10][20]. - The company has previously emphasized that unauthorized use of its brand name is illegal and has taken steps to clarify its position on brand management and quality assurance [27][28].

记者丨 闫硕 编辑丨季媛媛 视频丨柳润瑛 见习记者陈泽锴 一款南极磷虾油引发的造假风波，再次将同仁堂贴牌乱象推向台前。 近日，上海市消保委对市面上热销的15款国内外南极磷虾油产品开展了检测和调查，其中 一款标称"北京同仁堂99%高纯南极磷虾 油"的产品，磷脂含量为0，涉嫌造假。 这款涉事产品并非北京同仁堂直接生产，而是由其孙公司北京同仁堂（四川）健康药业有限公司（简称"四川健康药业"）负责经销， 实际生产代工方为安徽哈博药业有限公司（简称"哈博药业"），属于典型的贴牌模式。 12月15日下午，上海市消保委正式约谈了该产品的经销商与生产商， 哈博药业承认在生产过程中未添加其对外宣称的"南极磷虾油"； 产品包装按照四川健康药业要求制作 。 北京同仁堂陷信任危机 南极磷虾油在调节代谢与心血管保护、骨骼健康维护、神经保护与认知等方面有一定功效。 最近，南极磷虾油成为健康圈的"香饽 饽"，但市面上南极磷虾油品牌繁多，价格差距悬殊，品质更是难以辨别 。 与此同时，同仁堂健康会员微信公众号发布声明：这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法程 序，对涉事企业进行起诉。目前，四川健康药业已停止经 ...